scholarly journals Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis

2018 ◽  
Vol 28 (6) ◽  
pp. 2516-2524 ◽  
Author(s):  
Joao V. Horvat ◽  
Manuela Durando ◽  
Soledad Milans ◽  
Sujata Patil ◽  
Jessica Massler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diffusion Coefficient ◽  
Cancer Diagnosis ◽  
Menopausal Status ◽  
Breast Cancer Diagnosis ◽  
Diffusion Weighted Mri ◽  
Background Parenchymal Enhancement ◽  
Apparent Diffusion ◽  
Apparent Diffusion Coefficient Mapping ◽  
Parenchymal Enhancement

scholarly journals Correlation Between Mammographic Breast Density, Breast Tissue Type in Ultrasonography, Fibroglandular Tissue, and Background Parenchymal Enhancement in Magnetic Resonance Imaging

2018 ◽  
Vol 12 ◽  
pp. 117822341877197 ◽  
Author(s):  
Afsaneh Alikhassi ◽  
Seyedeh Nooshin Miratashi Yazdi ◽  
Hedieh Akbari ◽  
Sona Akbari Kia ◽  
Masoud Baikpour
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Breast Density ◽  
Menopausal Status ◽  
Mammographic Breast Density ◽  
Resonance Imaging ◽  
Imaging Studies ◽  
Background Parenchymal Enhancement ◽  
Parenchymal Enhancement

Objective: Breast cancer is the most common malignancy in the female population, and imaging studies play a critical role for its early detection. Mammographic breast density (MBD) is one of the markers used to predict the risk stratification of breast cancer in patients. We aimed to assess the correlations among MBD, ultrasound breast composition (USBC), fibroglandular tissue (FGT), and the amount of background parenchymal enhancement (BPE) in magnetic resonance imaging, after considering the subjects’ menopausal status. Methods: In this retrospective cross-sectional study, the medical records’ archives in a tertiary referral hospital were reviewed. Data including age, menopausal status, their mammograms, and ultrasound assessments were extracted from their records. All of their imaging studies were reviewed, and MBD, USBC, FGT, and BPE were determined, recorded, and entered into SPSS software for analysis. Results: A total of 121 women (mean age = 42.7 ± 11.0 years) were included, of which 35 out of 115 (30.4%) had reached menopause. Using the Jonckheere-Terpstra test for evaluating the trends among above mentioned 4 radiologic characteristics in the total sample population, a significant positive relation was found between each of these paired variables: (1) USBC-MBD ( P = .006), (2) FGT-MBD ( P = .001), (3) USBC-BPE ( P = .046), (4) USBC-FGT ( P = .036), and (5) BPE-FGT ( P < .001). These trends were not found to be significant among premenopausal subjects. Conclusions: Considering the trends between different measures of breast density in the 3 radiologic modalities, these factors can be used interchangeably in certain settings.

Factors associated with weight gain during endocrine therapy for breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 12076-12076
Author(s):  
Anna-Carson Rimer Uhelski ◽  
David Lim ◽  
Amanda L. Blackford ◽  
Jennifer Y. Sheng ◽  
Claire Frances Snyder ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Weight ◽  
Weight Gain ◽  
Cancer Diagnosis ◽  
Menopausal Status ◽  
Breast Cancer Diagnosis ◽  
Pain Interference ◽  
Factors Associated ◽  
Menopausal Women ◽  
Post Menopausal

12076 Background: Weight gain is common after a breast cancer diagnosis. The incidence of and risk factors for weight gain during adjuvant endocrine therapy (ET) are poorly described. Limited data support an association between emergent symptoms and weight gain after a breast cancer diagnosis. Methods: We enrolled women with stage 0-III breast cancer initiating ET in a prospective clinic-based cohort. We assessed symptoms with the FACT-ES and PROMIS pain interference, depression, anxiety, fatigue, sleep disturbance and physical function measures at baseline (BL), 3, 6, 12, 24, 36, 48 and 60 months (mo). We defined emergent symptoms at 3 and/or 6 mo as worsening of 4 points from BL on PROMIS measures and 5 points from BL on the FACT-ES. We abstracted weight and menopausal status from charts. The primary outcome of this secondary analysis was weight gain (dichotomized as ≥5% vs < 5% of body weight compared to BL) through 60 mo. We evaluated the association between weight gain during ET and menopausal status. We also evaluated the associations between clinicodemographic factors and emergent symptoms with weight gain and if these associations differed by menopausal status. We performed logistic regression modeling with GEE to account for the longitudinal design. We identified a multivariable model for the set of factors associated with weight gain among pre-menopausal women taking ET. Results: 309 of 321 participants with BL and ≥1 follow-up (FU) weight were included. 263 (85%) had stage I-II disease, 99 (32%) were pre-menopausal, 259 (84%) were White and 32 (10%) were Black. Prior to ET, 45% had mastectomy, 66% had radiation, and 28% received chemotherapy. 4% of pre- and 82% of post-menopausal participants initiated an aromatase inhibitor (AI); all others initiated tamoxifen (Tam). 17% of pre-menopausal participants received ovarian suppression. At BL, 75% of Black and 59% of White participants were overweight/obese. With a median FU of 56 mo, 51% of pre- and 34% of post-menopausal participants gained ≥5% body weight (OR 1.09, 95% CI 1.07-1.13, p < 0.001). For each PRO measure, > 20% of participants had emergent symptoms. Worsening of physical function and pain interference scores at 3 and/or 6 mo were differentially associated with weight gain according to menopausal status (interaction p-values ≤0.05). On multivariate analysis, factors associated with weight gain among pre-menopausal participants were ET (AI vs Tam) (OR 2.8, 95% CI 0.90- 8.77, p = 0.08), prior mastectomy (OR 2.06, 95% CI 0.89-4.77, p = 0.09), emergent pain interference (OR 2.49, 95% CI 0.99-6.24, p = 0.05) and race (White vs other) (OR 7.13, 95% CI 1.29-39.4], p = 0.02). Conclusions: Weight gain during ET for breast cancer is more frequent among pre-menopausal than post-menopausal women. Worsening pain soon after ET initiation, receipt of AI, prior mastectomy and race may identify pre-menopausal women at risk for weight gain for whom prevention strategies are a priority.

scholarly journals Association between MRI background parenchymal enhancement and lymphovascular invasion and estrogen receptor status in invasive breast cancer

2019 ◽  
Vol 92 (1103) ◽  
pp. 20190417 ◽  
Author(s):  
Jun Li ◽  
Yin Mo ◽  
Bo He ◽  
Qian Gao ◽  
Chunyan Luo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Invasive Breast Cancer ◽  
Clinical Characteristics ◽  
Lymphovascular Invasion ◽  
Menopausal Status ◽  
Pathological Examination ◽  
Background Parenchymal Enhancement ◽  
Parenchymal Enhancement ◽  
Er Status

Objectives: In magnetic resonance imaging (MRI), background parenchymal enhancement (BPE) is associated with breast cancer risk, but the associations between BPE and clinical characteristics and histological features are unknown. This study aimed to investigate the association between BPE and clinical characteristics (including age, menopausal status, and tumor histological characteristics) in patients with invasive breast cancer. Methods: This was a retrospective study of 163 patients with invasive breast cancer (164 lesions, 1 patient had bilateral cancer) confirmed by surgery and pathological examination, treated between January 2014 and December 2016 at our university (Kunming Medical University). The patients were divided into two groups: extremely minimal and mild enhancement (low BPE group, n = 78) vs moderate and marked enhancement (high BPE group, n = 86). Results: Compared with the low BPE group, the high BPE group showed higher frequencies of patients < 50 years of age (88% vs 38%, p < 0.0001), premenopausal (87% vs 29%, p < 0.0001), T1 staging (35% vs 15%, p = 0.027), Grade II (57% vs 37%, p = 0.03), lymphovascular invasion (83% vs 13%, p < 0.0001), and positive estrogen receptor (ER) (79% vs 42%, p < 0.0001). The Spearman correlation coefficients (r) between BPE and age, menopausal status, lymphovascular invasion, and ER status were −0.521 (p < 0.0001), –0.588 (p < 0.0001), 0.697 (p < 0.0001), and 0.377 (p < 0.0001), respectively. Conclusion: BPE is negatively associated with age and menopausal status, and is positively associated with lymphovascular invasion and positive ER status. Advances in knowledge: BPE is not correlated with T staging and histological classification in patients with invasive breast cancer.

scholarly journals Impact of Mammography Screening Interval on Breast Cancer Diagnosis by Menopausal Status and BMI

2013 ◽  
Vol 28 (11) ◽  
pp. 1454-1462 ◽  
Author(s):  
Kim Dittus ◽  
◽  
Berta Geller ◽  
Donald L. Weaver ◽  
Karla Kerlikowske ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Mammography Screening ◽  
Menopausal Status ◽  
Breast Cancer Diagnosis ◽  
Screening Interval
Sign in / Sign up

Export Citation Format

Share Document